Oncology
Curis announces dosing of first patient in Hedgehog antagonist Phase I clinical trial
Published in Medical Letter on the CDC and FDA, March 4th, 2007
The Phase I trial is designed as an open-label study of a systemic Hedgehog antagonist in patients with locally advanced or metastatic cancers that are refractory to standard therapy or for whom no standard therapies exist. The primary objectives of the Phase I trial are to evaluate the safety and tolerability of escalating doses of the Phase I...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Drug Discovery
New findings from Center for Drug Evaluation and Research in the area of drug discovery described - Pharmacology
Researchers from Center for Drug Evaluation and Research publish new studies and findings in the area of pharmacology - Allergy & Immunology
Allergy Therapeutics reports positive phase 2 U.S. FDA meeting on Pollinex Quattro Ragweed - Benign Prostate Hypertrophy
Spectrum initiates phase 2b trial for ozarelix in patients with benign prostate hypertrophy - Business & Finance
Vascular Solutions reports net sales in Q4 2006 of $11.5 million, up 30% over year ago - Business Update
Aastrom receives orphan drug designation from U.S. FDA for dilated cardiomyopathy - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
